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Abstract
Background: Insulin sensitivity has been enhanced by electroacupuncture (EA) in rats, but the EA
phenomenon in an insulin resistant state is still unclear. This study reports the use of a large dose
of prednisolone to evaluate the effects of EA in a state of insulin resistance.
Methods: The plasma levels of free fatty acids (FFAs) were estimated in steroid-background rats
(SBRs) and compared with those in healthy rats treated with normal saline. In addition, plasma
glucose and endogenous insulin levels were assayed to calculate the homeostasis model assessment
(HOMA) index. Intravenous glucose tolerance test (IVGTT) was carried out to compare glucose
tolerance. The SBRs were randomly divided into EA-treatment and non-EA treatment groups and
15-Hz EA was applied to the bilateral Zusanli acupoints to investigate its effects on insulin
resistance. In addition to an insulin challenge test (ICT) and IVGTT, the plasma levels of FFAs were
measured and western blot was performed to help determine the effects of EA on the insulin
resistant state.
Results: The plasma levels of FFAs increased markedly in SBRs, the HOMA index was markedly
higher, and glucose tolerance was impaired. EA improved glucose tolerance and insulin sensitivity
by decreasing the plasma levels of FFAs. Further, the insulin signaling proteins (IRS1) and glucose
transporter isoform protein (GLUT4) in skeletal muscle inhibited by prednisolone recovered after
EA.
Conclusion: Insulin resistance was successfully induced by a large dose of prednisolone in male
rats. This insulin resistance can be improved by 15 Hz EA at the bilateral Zusanli acupoints, as
shown by decreased plasma levels of FFAs.
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Background
Insulin resistance is a metabolic disorder caused by
decreased biological responses to insulin [1]. Insulin sig-
naling is a cascade of events initiated when insulin binds
to the alpha-subunits of its surface receptor. The receptor
beta-subunits then autophosphorylate, leading to activate
tyrosine phosphorylation of insulin receptor substrates
(IRSs) [2]. The binding of the regulatory subunit of phos-
phatidylinositol 3-kinase (PI3K) to IRSs activates PI3K
and Akt, which are also called protein kinase B (PKB). The
activation of this process is necessary for insulin to regu-
late glucose transporter 4 (GLUT4) protein translocation
from the cytosol to the membrane for glucose transporta-
tion in skeletal muscle [3]. Theoretically, insulin resist-
ance may be due to one or more of the following: (a)
deficiency or defects in insulin receptors, (b) inactivation
of GLUT4 proteins, or (c) deficiency of GLUT4 proteins
[4]. This study measures the IRS1 and GLUT4 levels of EA
and non-EA samples for both steroid background and
saline groups to evaluate the possible effects of EA on
insulin resistance.
Most patients with type 2 diabetes mellitus (DM) exhibit
tissue insensitivity to insulin [5]. This disorder is related to
genetic factors, and may be aggravated by other factors
including a sedentary lifestyle, abdominal visceral obesity
and a high-carbohydrate diet [6]. Other studies show that
many circulating insulin inhibitors, such as anti-insulin
antibodies, free fatty acids (FFAs), growth hormones, and
glucocorticoids, are involved in the reduction of insulin
sensitivity [7,8].
Most glucocorticoids are produced in the adrenal cortex.
They have multiple functions, but mainly increase hepatic
gluconeogenesis and inhibit peripheral glucose uptake in
both muscle and adipose tissues. In adipose tissue, excess
glucocorticoids lead to lipolysis, releasing FFAs and induc-
ing insulin resistance [9,10] by inactivating GLUT4 trans-
location from the cytosol to the cell membrane for glucose
uptake [11].
Researchers have indicated that glucocorticoids can
inhibit glucose uptake at one or more steps along the
insulin signaling pathway at the cellular level. Dexameth-
asone impairs insulin signaling and glucose transport by
depleting IRS1, PI3K, and protein kinase B in primary cul-
tured rat adipocytes [12]. In a previous study on the rela-
tionship of insulin resistance with blood pressure, chronic
low-dose subcutaneous dexamethasone (2 ug/day) was
given to Wistar rats for 4 weeks to induce insulin resist-
ance [13]. In addition, another study showed that gluco-
corticoids induce the redistribution of fat from the
periphery to the central abdominal compartment and
increase visceral lipolysis, elevating plasma triglyceride
(TG) and FFA levels. Reducing muscle glucose uptake also
lowers glucose transportation activity [14].
Although some drugs can improve insulin resistance [15],
the goal of many researchers is the development of new,
more effective alternative therapies with fewer side effects.
Acupuncture treatment is a component of traditional Chi-
nese medicine (TCM), and has been used for over two
thousand years. The commonly used acupoints for DM-
like syndromes include Pishu (BL20), Geshu (BL17),
Zhongwan (CV12), Sanyinjiao (SP6), Neiguan (PC6),
and Zusanli (ST36) [16]. Researchers have recently begun
using electroacupuncture (EA) instead, as it combines tra-
ditional needle acupuncture with an electrical current
passing through the needles into the acupoints to produce
hypoglycemic responses. Research suggests that EA at dif-
ferent frequencies causes the release of endogenous opi-
oid peptides that activate specific receptors [17].
Researchers have also examined opioid receptors in the
pancreas to determine their roles in the regulation of
plasma glucose concentrations [18,19]. In addition, beta-
endorphins enhance insulin secretion [20]. Applying EA
to the Zhongwan acupoint induces the secretion of beta-
endorphins, leading to insulin-dependent lowering
plasma glucose action in diabetic rats [21].
Acupuncture can also lower plasma FFAs and lipid levels
by altering citrate or glucose metabolism in the liver [22].
Moreover, EA at the Zhongwan (CV12) acupoint of Psam-
momys obesus produces a prolonged and sustained
hypoglycemic effect by elevating insulin sensitivity [23].
However, the mechanisms by which EA improves insulin
resistance remain unclear. The aim of this study is to
determine if a single EA treatment can inhibit the develop-
ment of glucocorticoid-altered insulin sensitivity and
exploring the mechanisms of EA by way of assaying
plasma FFAs and insulin signal proteins.
The experiments in this study applied intravenous glucose
tolerance test (IVGTT) and insulin challenge test (ICT) to
evaluate the effect of EA on insulin resistant steroid-back-
ground rats (SBRs). In addition, whole-animal insulin
resistance was measured using the homeostasis model
assessment (HOMA) index [24]. Finally, this study evalu-
ates insulin signal proteins to investigate the mechanisms
by which EA improves the insulin resistance of SBRs.
Methods
Animal Models
Male Wistar rats weighing 300–340 g and aged 8–10
weeks were used in this study. Steroid-induced insulin
resistant rats were produced by intraperitoneal injection
(i.p.) of 40 mg/kg prednisolone after the rats had fasted
for 12 hours. Insulin resistance after the prednisoloneBMC Complementary and Alternative Medicine 2009, 9:26 http://www.biomedcentral.com/1472-6882/9/26
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injection was confirmed by intravenous glucose tolerance
test and the HOMA index. These steroid background rats
were prepared for evaluating the effect of EA on insulin
resistance. The rats were maintained in the Animal Center
of China Medical University, Taiwan, under a 12:12 h
light-dark cycle (light on at 6:00 a.m.) in a temperature
controlled room (25 ± 1°C). Food (Purina Rat Chow) and
water were available ad libitum. All animals were anesthe-
tized with 40 mg/kg pentobarbital (MTC Company, Can-
ada) i.p. before all the experiments in this study. Animals
were treated in accordance with the National Institute of
Health (NIH) Guide for the Care and Use of Laboratory
Animals, and this protocol was approved by an ethical
committee in China Medical University, Taichung, Tai-
wan.
Evaluating methods of insulin resistance in SBRs
At first, fasting normal male rats (n = 22) were randomly
divided into a steroid group (SG) and a control (normal
saline) group (CG). The SG rats were treated with a single
intraperitoneal injection of large-dose prednisolone (40
mg/kg) dissolved in normal saline. The CG rats were
treated with an intraperitoneal injection of the same vol-
ume of normal saline. Blood samples were drawn from
the femoral veins at 30, 60, and 90 min post-treatment to
estimate the plasma FFA levels of both groups. The plasma
FFA levels (meq/l) were determined using a non-esterified
fatty acid kit (Randox Laboratories, Canada Ltd.) and
automatic spectrophotometers (COBAS system). Whole-
animal insulin resistance was assessed using the HOMA
index, as described previously [24]. This procedure
involves the simultaneous evaluation of the fasting
plasma insulin levels (μU/ml) multiplied by the fasting
plasma glucose (mmol/l) and divided by 22.5. Endog-
enous plasma insulin levels (pmol/l) were determined
using a commercial kit (Roche Elecsys systems) and the
electrochemiluminescence immunoassay (ECLIA)
method. Plasma glucose levels were measured using a
spectrophotometer system (COBAS). At the end of the
test, plasma insulin and glucose levels were assayed to cal-
culate differences in the HOMA index between the two rat
groups.
To confirm insulin resistance by IVGTT, fasting normal
male rats (n = 26) were randomly divided into SG and CG
groups. After injection of prednisolone i.p., IVGTT was
processed by intravenous injection of 1 mg/kg glucose
into the femoral veins of the SG group rats under anesthe-
sia. The same IVGTT process was carried out on the CG
rats. During the IVGTT, blood samples were drawn from
the femoral veins of the rats at 0, 15, 30, 60, and 90 min
after injections for plasma glucose assay in each group.
The changes in the plasma glucose levels were then com-
pared between the SG and CG groups.
Electroacupuncture
In the EA experiment, the bilateral Zusanli acupoints
located at the anterior tibia muscle near the knees were
identified based on previous studies [25,26]. After adjust-
ing the EA apparatus to 15 Hz/10 mA (Han's Healthronics
Likon, Taipei, Taiwan), acupuncture needles (0.5 inch/32
gauge) were inserted 2–5 mm into the muscle layer of the
selected acupoints. The positively charged (red pole) clip
was connected to the right needle and the negatively
charged (black pole) clip was connected to the left needle.
Evaluating the effects of EA on SBRs
Another experiment was conducted to evaluate the effects
of EA on insulin resistant SBRs and the changes in plasma
insulin levels. Fasting normal male rats (n = 16) were first
randomly divided into EA and non-EA groups. The two
groups rats were then treated with prednisolone as
described above, and allowed to rest for 90 min. The insu-
lin resistant SBRs then received EA for 60 min under
anesthesia, and were then compared with the non-EA
group. An IVGTT was performed to compare the changes
in plasma glucose level between the EA and non-EA
groups at 0, 15, 30, 60, and 90 min post-treatment.
Endogenous plasma insulin levels (pmol/l) were also esti-
mated in the two group rats at 0, 15, 30, 60, and 90 min
post-treatment. Further study of ICT was conducted to
evaluate the effects of EA on plasma glucose levels and
FFAs levels during an insulin challenge test on insulin
resistant SBRs. The two groups rats (n = 18) were treated
with prednisolone as described above and allowed to rest
for 90 min. The SBRs were then randomly divided into EA
and non-EA groups. The EA group rats received EA for 60
min under anesthesia, and then compared with the non-
EA group. During ICT, 1 IU/kg i.p. of regular insulin
(NovoNordisk Company, Denmark) was applied to both
rat groups to compare plasma glucose and FFAs levels at
0, 30, and 60 min post-treatment.
In western blot analysis, fasting normal male rats (n = 18)
were randomly divided into EA, non-EA (receiving the
same treatments as described above), and normal saline
(did not receive EA and prednisolone) groups. Blood sam-
ples were taken at the beginning and end of EA to deter-
mine the levels of plasma glucose and insulin for
calculating the HOMA index. These blood samples were
also assayed of plasma levels of FFAs, the percentage
change (%) was calculated between the beginning and
end of EA. At the end of EA, a part of gastrocnemius mus-
cles in the back of the lower legs of the rats were cut off as
sample for analysis of insulin signal proteins (IRS1,
GLUT4), and actin served as a control. The muscle sam-
ples were homogenized in buffer solution before centrifu-
gation at 13000 rpm. The obtained supernatant was used
to estimate the amount of protein using an assay kit (Bio-BMC Complementary and Alternative Medicine 2009, 9:26 http://www.biomedcentral.com/1472-6882/9/26
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Rad Laboratories, CA., USA). This supernatant (protein)
was added to 4× loading dye, and boiled for 15 min at
95°C for denaturing. This process produces separating
(8%) and stacking gel. Then, protein (90 ug/ml) in the
buffer solution was loaded into each well for electro-
phoresis. Proteins were electrophoretically transferred to
polyvinylidene difluoride membranes at 4°C. The mem-
branes were then blocked with 5% nonfat dry milk in
phosphate buffered saline (PBS) for 1 hr at room temper-
ature and incubated with the specific primary antibodies
(Santa Cruz Biotechnology, Inc, CA., USA). After the
membranes were washed in a buffer containing 0.1%
Tween 20 in 1× PBS, blots were incubated with a horse-
radish peroxidase-linked specific second antibody (Santa
Cruz Biotechnology, Inc) followed by enhanced chemilu-
minescence detection using ECL reagent plus (Perk-
inElmer Life Sciences, Inc., USA). Band intensities were
quantified by densitometry to observe the target proteins.
Statistical Analysis
Results were calculated as a percentage change of the ini-
tial value according to the formula (Xi-Xt) × 100/Xi, where
Xi is the initial level and Xt is the level after treatment. Sta-
tistical analysis was performed using SPSS analytical soft-
ware. Data was expressed as mean ± SEM, and repeated
measures analysis of variance (ANOVA) was performed to
analyze plasma glucose and other variables. The source of
significant differences was determined by post hoc com-
parison. The non-parametric Mann-Whitney test or Stu-
dent's t-test was also applied to compare the differences
between the two independent groups. A p-value less than
0.05 was considered statistically significant.
Results
Elevating insulin resistance in rats after prednisolone 
administration
After treatment with a large dose of prednisolone, the rats'
plasma levels of FFAs gradually increased from 30 to 90
min. The SG group exhibited significantly higher plasma
levels of FFAs at 90 min than the CG group. The percent-
age increase in plasma levels of FFAs at 60 min for the SG
group was 38%, which was higher than the 11% increase
in the CG group. At 90 min, the percentage increase in the
SG group was 66%, while it was only 15% (p < 0.05) in
the CG group (Table 1).
In addition, the SG exhibited a higher HOMA index than
the CG group at 90 min (Table 2). Although the plasma
levels of glucose were not significantly different between
the two groups, the plasma levels of insulin in the SG
group increased markedly at 90 min after the injection of
prednisolone (Table 2). During the IVGTT, the SG had
higher plasma glucose levels than the CG group from 30
to 90 min (Figure 1). The plasma glucose level at 30 min
was 8.2 ± 2.4 mmol/l in the CG group, which was mark-
edly lower than the 11.1 ± 2.3 mmol/l result in the SG
group (p < 0.01). At 60 min, the plasma glucose level was
5.5 ± 0.7 mmol/l in the CG group, which was still lower
than the 7.0 ± 1.7 mmol/l result in the SG group (p <
0.005). This trend remained unchanged at 90 min (p <
0.05).
Effect of EA on SBRs evaluated by IVGTT
The IVGTTs in this study revealed significant changes in
plasma glucose lowering effect in the EA group compared
with the non-EA group from 15 to 90 min post-treatment
(Figure 2(A)). Figure 2(A) shows that the increase in
plasma glucose levels after the injection of glucose was
lower in the EA group than in the non-EA group. The
plasma level of glucose at 90 min was 5.1 ± 0.6 mmol/l in
the EA group, which was markedly lower than the 7.0 ±
0.9 mmol/l result in the non-EA group (p < 0.005). The
differences in plasma levels of insulin between the EA and
non-EA groups were not statistically significant at 90 min
(Figure 2B).
Effects of EA on SBRs evaluated by ICT
Table 3 shows that the ICT revealed a higher percent
decrease in glucose in the EA group than that in the non-
EA group. At the end of the test, the percentage decrease in
glucose in the EA group was 77%, while that in the non-
EA group was only 42% (p < 0.01). At the same time, the
EA group had lower plasma levels of FFAs than the non-
EA group.
Effects of EA on SBRs evaluated by HOMA index and 
plasma FFA levels
The EA group in this study exhibited a lower HOMA index
and a lower percentage of elevation in plasma FFAs com-
pared with the non-EA group at 60 min after initiating the
test in SBRs (Table 4). Although the plasma levels of glu-
cose did not change significantly after a single dose of
prednisolone in the non-EA group compared with the
group treated with normal saline, the EA group exhibited
a significantly lower plasma level of glucose. No differ-
ences in plasma insulin levels appeared between the EA
and non-EA groups, but both groups showed higher
Table 1: Plasma FFA levels in normal Wistar rats treated with 
normal saline or prednisolone
Time (n = 11) 30 min 60 min 90 min
CG: Normal Saline 1.23 ± 0.5 1.29 ± 0.4 1.25 ± 0.5
SG: Prednisolone 1.01 ± 0.2, a 1.36 ± 0.2, b 1.64 ± 0.3, c *
Values given as mean ± SEM (meq/l) after treatment; n = number of 
animals; CG = control group; SG = steroid group; letters a, b, and c 
indicate statistical significance compared with each other using 
ANOVA with LSD post-hoc test: a < b < c, p < 0.05. Data from each 
group were compared using the non-parametric Mann-Whitney test. 
*p < 0.05BMC Complementary and Alternative Medicine 2009, 9:26 http://www.biomedcentral.com/1472-6882/9/26
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Table 2: Homeostasis model assessment (HOMA) index of Wistar rats treated with normal saline or prednisolone 40 mg/kg i.p.
After 90 min (n = 8) Glucose (mmol/l) Insulin (pmol/l) HOMA index
CG: Normal Saline 5.7 ± 0.6 0.27 ± 0.2 1.7 ± 1.2
SG: Prednisolone 5.8 ± 0.8 0.84 ± 0.4 * 7.29 ± 3.0 *
Values are given as mean ± SEM after treatment, n = number of animals. Data from each group were compared using the non-parametric Mann-
Whitney test. *p < 0.05
plasma insulin levels than the group treated with normal
saline alone (Table 4).
Effect of EA on the insulin signaling protein expression of 
SBRs
Significantly lower IRS1 and GLUT4 protein expression
occurred in rats in the non-EA group receiving pred-
nisolone 60 min post-treatment. No significant differ-
ences in IRS1 or GLUT4 appeared between the group
treated with normal saline only and the group of SBRs
that received EA treatments (Figure 3). The inhibition of
IRS1 and GLUT4 proteins in SBRs was not seen in rats
treated by EA.
Discussion
According to traditional Chinese medicine theory, differ-
ent acupoints have different effects [27]. Previous studies
showed that EA stimulation at the bilateral Zusanli acu-
points produces a greater hypoglycemic response than
stimulation at the Zhongwan acupoint in normal rats
[25,28]. Also, using 15 Hz EA produces a better hypoglyc-
emic effect than 2 Hz EA [29]. Therefore, this study used
15 Hz EA on the bilateral Zusanli acupoints to explore its
effects on enhancing insulin sensitivity. The purpose of
this study is to evaluate whether or not EA stimulation can
improve insulin sensitivity by decreasing plasma FFAs lev-
els in steroid background rats with insulin resistance.
Glucocorticoids are important in the etiology of insulin
resistance through down-regulation of insulin signal pro-
teins. In a dose-dependent manner, steroids cause desen-
sitize the glucose transport system in muscle [30,31]. In
addition, glucocorticoid-related hyperglycemia is also
dose dependent [32]. Although there is still insufficient
studies to support the animal model of insulin resistance
caused by a large dose of prednisolone, this study presents
a faster method and a new animal model of elevating
short-term insulin resistance using a large dose of pred-
nisolone as background in normal Wistar rats, and using
IVGTT, HOMA index and FFA for the realization of steroid
induced insulin resistance. Further, this study shows the
effects of EA in SBRs with an insulin resistant state.
The data produced by comparing experiments between SG
and CG in this study shows that a large dose of pred-
nisolone effectively produces insulin resistance. We can-
not rule out the possibility that higher insulin levels
(Table 2) are the result of impaired insulin clearance
rather than increased compensatory secretion. However,
the expression of insulin signal proteins (IRS1 and
GLUT4) was inhibited in SBRs, which is why pred-
nisolone produces insulin resistance.
This study determines the hypoglycemic effects of EA in
SBRs using IVGTTs and ICTs to investigate ways to
decrease insulin resistance or inhibit the development of
insulin resistance. During the IVGTT experiment, the EA
group exhibited lower plasma glucose levels than the non-
EA group in SBRs (Figure 2A). The EA group and the non-
EA group did not exhibit significantly different plasma
insulin levels in these SBRs (Figure 2B). This may be
because insulin secretion was stimulated by exogenous
glucose or because prednisolone was applied to the SBRs
during the IVGTT. Thus, EA had no further effect on
increasing insulin secretion. This result is compatible with
Intravenous glucose tolerance tests (IVGTTs) to evaluate the  insulin resistance in SBRs rats Figure 1
Intravenous glucose tolerance tests (IVGTTs) to 
evaluate the insulin resistance in SBRs rats. The 
plasma glucose levels of SBRs and the control group were 
compared using an independent t-test. *p < 0.05; **p < 0.01.
** 
* 
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(A) Plasma glucose levels and (B) plasma insulin levels for steroid background rats undergoing IVGTT Figure 2
(A) Plasma glucose levels and (B) plasma insulin levels for steroid background rats undergoing IVGTT. Pred-
nisolone + EA group = SBRs receiving EA for 60 min at the bilateral Zusanli acupoints. Prednisolone + non-EA group = SBRs 
without EA. *p < 0.05; **p < 0.01, EA vs. non-EA at the same time point.
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previous studies, which showed that 15 Hz EA on the
bilateral Zusanli acupoints significantly lowers plasma
glucose levels during an IVGTT in normal Wistar rats. In
addition, the EA group and the non-EA group showed no
differences in plasma insulin levels in normal Wistar rats
[33]. In summary, 15 Hz EA on the bilateral Zusanli acu-
points can enhance plasma glucose lowering effects in
both normal Wistar rats and SBRs, not through an
increase in insulin secretion, but by enhancing the insulin
sensitivity of the target organ. Also, a non-insulin depend-
ent hypoglycemic mechanism may be considered in 15
Hz EA on the bilateral Zusanli acupoints in our unpub-
lished results. The results in Table 4 illustrate this infer-
ence. The EA group and the non-EA group had the same
plasma insulin levels, but the EA group had lower plasma
glucose levels than the non-EA group. Although Figure 1
and 2 report these results using the parametric statistical
method with higher deviation, this study also uses non-
parametric statistical methods, such as the Mann-Whitney
test, to double check these results, obtaining the same
trend as the results using by parametric statistical method
in this study.
In the ICT, hypoglycemic effects were increased in the EA
group compared with the non-EA group of SBRs. This test
helps reveal whether or not EA enhances insulin sensitiv-
ity in SBRs given exogenous insulin. The results of this
study agree with previous studies, which showed that 15
Hz EA on the bilateral Zusanli acupoints induces signifi-
cantly higher hypoglycemic activity in normal Wistar rats
and streptozotocin (STZ)-induced diabetic rats than in
experimental animals without EA during an ICT [33]. In
addition, more hypoglycemic effects were observed at 60
min in SBRs which received EA during ICT (from 6.3 ± 0.6
to 1.4 ± 0.4 mmol/l below the normal range) than those
without EA (from 6.3 ± 0.7 to 3.8 ± 1.3 mmol/l; Table 3).
Furthermore, there was a marked decrease in FFA levels
(from 1.2 ± 0.3 to 0.7 ± 0.2 meq/l below the normal
range) at 60 min in the EA group of SBRs during ICT than
the SBRs without EA (Table 3). In summary, a decrease in
plasma FFA levels may play an important role in improv-
ing insulin sensitivity when using 15 Hz EA on the bilat-
eral Zusanli acupoints during ICT. Furthermore, EA
reversed the low expression of insulin signal proteins
(IRS1, GLUT4) in SBRs (Figure 3) and reduced the HOMA
index in SBRs to a level similar to that in the group that
received normal saline (Table 4). Therefore, it is reasona-
ble to suppose that EA can improve insulin resistance in
SBRs by decreasing the plasma FFA levels and recovering
insulin signal proteins. This implies that there is an
increase in insulin activity after using EA, although further
study of the insulin signal change mechanisms is
required.
Conclusion
Using EA at the bilateral Zusanli acupoints, this study tests
the hypothesis that EA can improve insulin resistance by
lowering plasma free fatty acids in SBRs male rats. Further
clinical trials in humans should be undertaken to obtain
more evidence for this hypothesis. However, a large dose
of prednisolone increased insulin resistance, and this
study successfully establishes a method of evaluating the
effect of EA in improving insulin sensitivity in an insulin
resistant state. In addition, results show that 15 Hz EA on
the bilateral Zusanli acupoints may improve insulin
resistance by decreasing the plasma FFA levels and recov-
ering the expression of insulin signal proteins (IRS1 and
GLUT4), which enhances insulin activity. Thus, EA should
Table 3: Effects of EA on plasma glucose and free fatty acids 
levels during an insulin challenge test in steroid background rats 
(SBRs)
Glucose mmol/l (n = 9) 0 min 30 min 60 min
Non-EA 6.3 ± 0.7 4.7 ± 1.2 3.8 ± 1.3
EA 6.3 ± 0.6 2.2 ± 0.7 ** 1.4 ± 0.4 **
FFA meq/l (n = 9)
Non-EA 1.1 ± 0.2 1.4 ± 0.3 1.4 ± 0.2
EA 1.2 ± 0.3 0.7 ± 0.3 ** 0.7 ± 0.2 **
Values are given as mean ± SEM after 12 hours of fasting and 30 min 
after giving prednisolone; n = number of animals, EA = experimental 
group which received electroacupuncture, non-EA = control group 
without electroacupuncture. **p < 0.01 vs. control group at the same 
time.
Table 4: Effects of EA on the homeostasis model assessment index in Wistar rats 60 minutes after treatment with a single large dose 
of prednisolone
Group (n = 6) Glucose (mmol/l) Insulin (pmol/l) FFA
(0–60 min) %
HOMA index
Normal Saline 6.5 ± 0.7, A1 0.27 ± 0.2, B2 17 ± 31, B3 1.8 ± 1.6, B4
EA (SBRs) 4.6 ± 0.6, B1 0.65 ± 0.2, A2 16 ± 20, B3 3.3 ± 1.1, B4
Non-EA (SBRs) 6.3 ± 0.3, A1 0.66 ± 0.2, A2 72 ± 31, A3 5.1 ± 1.0, A4
Values are given as mean ± SEM after treatment; n = number of animals, FFA = free fatty acids, HOMA = homeostasis model assessment, EA = 
electroacupuncture, SBRs = steroid background rats. Percentage (%) change from 0 to 60 min is shown in the column labeled FFA (0–60 min) %. 
The data for these four variables were compared using one way ANOVA. AX > BX, the least significant difference post hoc was taken; p < 0.05, the 
variable of "X = 1 to 4" represents the different indexes.BMC Complementary and Alternative Medicine 2009, 9:26 http://www.biomedcentral.com/1472-6882/9/26
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be considered a method of alternative therapy for pred-
nisolone induced insulin resistance.
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